详情页

当前位置：首页 > 详情页

Folate Receptor 4-Expressing T cell Is Associated with Disease-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.

14| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang 050017, China. [3]Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [4]Department of Breast Cancer Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [5]Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.

出处：

DOI：

ISSN：

摘要：

Folic acid receptor 4 (FR4) significantly downregulates the expression of regular T cells (Treg) and improves the effect of chemotherapy and PD-1/PD-L1 inhibitors. However, the FR4 expression in squamous cell carcinoma (ESCC) remains unclear.Patients with primary ESCC who visited our hospital between 1st February 2012 and 30th September 2016 were enrolled in this study. FR4 expressions in ESCC patients were detected by immunohistochemistry staining, and the association with clinical characteristics and the overall survival (OS) or disease-free survival (DFS) was analyzed.One hundred and forty-eight qualified cases of ESCC patients were retrieved, including 34 females. Ninety-four cases had lymph node metastasis (63.51%), 104 patients received adjuvant therapy (70.27%), and the rate of FR4 positive was 67.57% (100/148). Among FR4 positive patients, 75 cases received adjuvant therapy, and patients who received chemotherapy were significantly better than that of patients who did not receive chemotherapy. In patients with FR4 negative expression, 48 cases received adjuvant therapy, which was significantly worse than that of patients who did not receive chemotherapy.Postoperative adjuvant chemotherapy prolonged the survival in FR4 positive ESCC patients, whereas adjuvant therapy in patients with FR4 negative needs to be further improved.Copyright © 2022 Xiangmei Zhang et al.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2022]版：

大类 | 4 区医学

小类 | 3 区病理学 3 区生物工程与应用微生物 4 区遗传学 4 区医学：研究与实验

最新[2025]版：

无

影响因子： 0 最新[2024版] 0 最新五年平均 0 出版当年[2022版] 0 出版当年五年平均 3.464 出版前一年[2021版]

第一作者：

第一作者机构： [1]Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang 050017, China.

通讯作者：

通讯机构： [3]Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [4]Department of Breast Cancer Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：